The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis

Gynecologic Oncology

Volumn 124, Issue 1, 2012, Pages 134-141

  Romero, Iris L ^a   Lee, Wooseok ^a,c   Mitra, Anirban K ^a   Gordon, Ilyssa O ^a   Zhao, Yan ^b   Leonhardt, Payton ^a   Penicka, Carla V ^a   Mui, Keeley L ^a   Krausz, Thomas N ^a   Greene, Geoffrey L ^b   Lengyel, Ernst ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c Soonchunhyang University   (South Korea)

Author keywords

17 estradiol; Genetic mouse model; Hormone replacement therapy; Ovarian cancer; Selective estrogen receptor modulators

Indexed keywords

BAZEDOXIFENE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INVASION; CANCER PREVENTION; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ANTAGONISM; ENZYME PHOSPHORYLATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; ESTRADIOL; ESTRADIOL ANTAGONISTS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; INDOLES; MICE; MICE, TRANSGENIC; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; OVARY; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 83055181123     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.08.026     Document Type: Article

References (43)

1. S.S. Buys, E. Partridge, A. Black, C.C. Johnson, L. Lamerato, and C. Isaacs Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial JAMA 305 22 2011 2295 2303
2. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 4 2009 225 249
3. E. Lengyel Ovarian cancer development and metastasis Am J Pathol 177 3 2010 1053 1064
4. A.K. Folkins, E.A. Jarboe, M.H. Roh, and C.P. Crum Precursors to pelvic serous carcinoma and their clinical implications Gynecol Oncol 113 3 2009 391 396
5. Collaborative Group on Epidemiological Studies of Ovarian C V. Beral, R. Doll, C. Hermon, R. Peto, and G. Reeves Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls Lancet 371 9609 2008 303 314
6. C.M. Greiser, E.M. Greiser, and M. Doren Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis Hum Reprod Update 13 5 2007 453 463 (Pubitemid 47303949)
7. K.N. Danforth, S.S. Tworoger, J.L. Hecht, B.A. Rosner, G.A. Colditz, and S.E. Hankinson A prospective study of postmenopausal hormone use and ovarian cancer risk Br J Cancer 96 1 2007 151 156 (Pubitemid 46094654)
8. V. Beral, D. Bull, J. Green, and G. Reeves Ovarian cancer and hormone replacement therapy in the Million Women Study Lancet 369 9574 2007 1703 1710 (Pubitemid 46755369)
9. L.S. Morch, E. Lokkegaard, A.H. Andreasen, S. Kruger-Kjaer, and O. Lidegaard Hormone therapy and ovarian cancer JAMA 302 3 2009 298 305
10. C.L. Pearce, K. Chung, M.C. Pike, and A.H. Wu Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin Cancer 115 3 2009 531 539
11. J.S. Hildebrand, S.M. Gapstur, H.S. Feigelson, L.R. Teras, M.J. Thun, and A.V. Patel Postmenopausal hormone use and incident ovarian cancer: associations differ by regimen Int J Cancer 127 2010 2928 2935
12. V. Syed, G. Ulinski, S.C. Mok, G.K. Yiu, and S.M. Ho Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells Cancer Res 61 18 2001 6768 6776 (Pubitemid 32896499)
13. G.N. Armaiz-Pena, L.S. Mangala, W.A. Spannuth, Y.G. Lin, N.B. Jennings, and A.M. Nick Estrous cycle modulates ovarian carcinoma growth Clin Cancer Res 15 9 2009 2971 2978
14. S.H. Park, L.W. Cheung, A.S. Wong, and P.C. Leung Estrogen regulates snail and slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha Mol Endocrinol 22 9 2008 2085 2098
15. K. Hua, W. Feng, Q. Cao, X. Zhou, X. Lu, and Y. Feng Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer Int J Oncol 33 5 2008 959 967
16. M.A. Spillman, N.G. Manning, W.W. Dye, C.A. Sartorius, M.D. Post, and J.C. Harrell Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis Cancer Res 70 21 2010 8927 8936
17. L.A. Laviolette, K. Garson, E.A. Macdonald, M.K. Senterman, K. Courville, and C.A. Crane 17{beta}-estradiol accelerates tumor onset and decreases survival in a transgenic mouse model of ovarian cancer Endocrinology 151 3 2010 929 938
18. K.D. Hatch, J.B. Beecham, J.A. Blessing, and W.T. Creasman Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients Cancer 68 2 1991 269 271
19. J.A. Hurteau, M.F. Brady, K.M. Darcy, W.P. McGuire, P. Edmonds, and M.L. Pearl Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): a Gynecologic Oncology Group study Gynecol Oncol 119 2010 444 450
20. A.W. Kung, E.Y. Chu, and L. Xu Bazedoxifene: a new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis Expert Opin Pharmacother 10 8 2009 1377 1385
21. K.C. Chang, Y. Wang, P.V. Bodine, S. Nagpal, and B.S. Komm Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens J Steroid Biochem Mol Biol 118 2009 117 124
22. S.M. Lippman, and J.V. Heymach The convergent development of molecular-targeted drugs for cancer treatment and prevention Clin Cancer Res 13 14 2007 4035 4041 (Pubitemid 47105962)
23. C.P. Miller, M.D. Collini, B.D. Tran, H.A. Harris, Y.P. Kharode, and J.T. Marzolf Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens J Med Chem 44 11 2001 1654 1657 (Pubitemid 32852172)
24. D.M. Dinulescu, T.A. Ince, B.J. Quade, S.A. Shafer, D. Crowley, and T. Jacks Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer Nat Med 11 1 2005 63 70 (Pubitemid 40215839)
25. K.W. Sinkevicius, J.E. Burdette, K. Woloszyn, S.C. Hewitt, K. Hamilton, and S.L. Sugg An estrogen receptor-alpha knock-in mutation provides evidence of ligand-independent signaling and allows modulation of ligand-induced pathways in vivo Endocrinology 149 6 2008 2970 2979 (Pubitemid 351724534)
26. B.S. Komm, Y.P. Kharode, P.V. Bodine, H.A. Harris, C.P. Miller, and C.R. Lyttle Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity Endocrinology 146 9 2005 3999 4008 (Pubitemid 41175771)
27. J.R. Reel, J.C. Lamb IV, and B.H. Neal Survey and assessment of mammalian estrogen biological assays for hazard characterization Fundam Appl Toxicol 34 2 1996 288 305
28. I.L. Romero, I.O. Gordon, S. Jagadeeswaran, K.L. Mui, W.S. Lee, and D.M. Dinulescu Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice Cancer Prev Res (Phila Pa) 2 9 2009 792 799
29. M.W. Pfaffl A new mathematical model for relative quantification in real-time RT-PCR Nucleic Acids Res 29 9 2001 e45
30. P. Wang, S.M. Henning, and D. Heber Limitations of MTT and MTS-based assays for measurement of antiproliferative activity of green tea polyphenols PLoS One 5 4 2010 e10202
31. E. Lengyel, S. Ried, M.M. Heiss, C. Jager, M. Schmitt, and H. Allgayer Ras regulation of urokinase-type plasminogen activator Methods Enzymol 333 2001 105 116 (Pubitemid 32507302)
32. K. Sawada, A.R. Radjabi, N. Shinomiya, E. Kistner, H. Kenny, and A.R. Becker c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion Cancer Res 67 4 2007 1670 1679 (Pubitemid 46383393)
33. V. Syed, G. Ulinski, S.C. Mok, and S.M. Ho Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells J Natl Cancer Inst 94 8 2002 617 629 (Pubitemid 34498649)
34. S. Suga, K. Kato, T. Ohgami, A. Yamayoshi, S. Adachi, and K. Asanoma An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer Gynecol Oncol 105 2 2007 341 350 (Pubitemid 46613898)
35. R.P. La, V. Pesiri, M. Marino, and F. Acconcia 17beta-estradiol-induced cell proliferation requires estrogen receptor (ER) alpha monoubiquitination Cell Signal 23 7 2011 1128 1135
36. A.W. Brandenberger, M.K. Tee, and R.B. Jaffe Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues J Clin Endocrinol Metab 83 3 1998 1025 1028 (Pubitemid 28496985)
37. K.M. Lau, S.C. Mok, and S.M. Ho Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells Proc Natl Acad Sci USA 96 10 1999 5722 5727 (Pubitemid 29234685)
38. P. Pujol, J.M. Rey, P. Nirde, P. Roger, M. Gastaldi, and F. Laffargue Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis Cancer Res 58 23 1998 5367 5373 (Pubitemid 28551118)
39. T. Rutherford, W.D. Brown, E. Sapi, S. Aschkenazi, A. Munoz, and G. Mor Absence of estrogen receptor-beta expression in metastatic ovarian cancer Obstet Gynecol 96 3 2000 417 421
40. A. Flesken-Nikitin, K.C. Choi, J.P. Eng, E.N. Shmidt, and A.Y. Nikitin Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium Cancer Res 63 13 2003 3459 3463 (Pubitemid 36793020)
41. R. Wu, N. Hendrix-Lucas, R. Kuick, Y. Zhai, D.R. Schwartz, and A. Akyol Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways Cancer Cell 11 4 2007 331 333
42. M. Zillhardt, S.M. Park, I.L. Romero, K. Sawada, A.G. Montag, and T. Krausz Foretinib (GSK1363089), an orally available multi-kinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis Clin Cancer Res 17 12 2011 4042 4051
43. B.E. Henderson, and H.S. Feigelson Hormonal carcinogenesis Carcinogenesis 21 3 2000 427 433 (Pubitemid 30137927)